Do your Microsoft Excel spreadsheets pass FDA muster? Can they meet strict 21 CFR Part 11 standards? Would you like to learn a defined approach that can make your task simple and straightforward saving you both time and money? Order this hands-on learning experience led by a trusted spreadsheet validation expert. Training is critical for anyone in the drug or device industry who oversees or uses spreadsheets for data collection, data processing or data reporting.
It's every drug- and devicemaker’s worst nightmare — inspectors coming through your front door with the power to shut you down. They're highly trained … ruthlessly committed to spotting your tiniest flaws … and tough as nails. If only you could question investigators in detail … before an inspection. Maybe you'd learn what you need to do to pass. Would they tell you? The answer is yes.
The FTC is challenging a GlaxoSmithKline (GSK)-Teva patent settlement deal, filing an amicus brief that argues authorized generic agreements fall under the category of pay-for-delay deals and are anticompetitive. The FTC wants the U.S. District Court for the District of New Jersey to adopt the 3rd Circuit Court of Appeals’ recent ruling in K-Dur, and it argues that ruling effectively declared authorized generic deals illegal. Drug Industry Daily